Cationic Peptide Delivery of Antisense Oligonucleotides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The inefficient cellular uptake of antisense oligonucleotides (ODN) in the bladder, particularly in non-cancerous conditions, limits the effectiveness of therapeutic approaches for bladder diseases like overactive bladder, due to the intact urothelial barrier and poor permeability, and existing delivery methods are cumbersome or toxic.
Innovation Solution
A composition comprising anionic therapeutic or diagnostic agents, such as antisense oligonucleotides, combined with cationic peptides like protamine, which form non-covalent associations to facilitate their delivery into bladder cells, enhancing cellular uptake and retention without compromising the bladder barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naked antisense oligonucleotides are instilled into the bladder, then the therapeutic agent can reach the target tissue, but cellular uptake is inefficient due to the intact urothelial barrier
Solution Approach 1:
The patent uses cationic peptides as intermediary carriers to mediate the delivery of anionic antisense oligonucleotides across the urothelial barrier. The cationic peptide forms non-covalent complexes with the anionic ODN, enabling the complex to interact with and traverse the cellular membrane, thereby significantly improving cellular uptake efficiency while maintaining therapeutic effectiveness
Solution Approach 2:
The patent changes the physical-chemical parameters of the therapeutic agent by complexing the anionic ODN with cationic peptides. This parameter change (from naked anionic ODN to cationic peptide-ODN complex) fundamentally alters the interaction with the urothelial barrier, enabling efficient cellular uptake without compromising the integrity of the barrier
2Productivity
If high concentrations of naked ODN are instilled to improve uptake, then cellular absorption increases in cancerous conditions, but the bladder barrier function is compromised and systemic side effects occur
Solution Approach 1:
The cationic peptide acts as a protective intermediary that enables efficient ODN delivery at lower concentrations. The peptide carrier facilitates specific interaction with target cells through receptor-mediated endocytosis, achieving high uptake efficiency without requiring the high concentrations that would otherwise damage the bladder barrier or cause systemic absorption
Solution Approach 2:
The patent employs phosphorothioate-modified ODN that mimics natural DNA structure and function while providing enhanced stability and resistance to nucleolytic degradation. This modified version achieves therapeutic effects at lower concentrations without compromising bladder barrier integrity
3Productivity
If cationic lipids are used to deliver ODN, then cellular delivery is improved, but organic solvents and expert handling are required for formulation
Solution Approach 1:
The patent replaces complex cationic lipid formulations with simple cationic peptide carriers that can be prepared as straightforward aqueous solutions. The cationic peptide-ODN complexes are stable and can be administered without specialized formulation techniques, eliminating the need for organic solvents and expert handling while maintaining high delivery efficiency
Solution Approach 2:
The patent changes the carrier material from cationic lipids requiring organic solvent formulation to cationic peptides that form stable complexes in aqueous solutions. This parameter change simplifies the formulation process, reduces device complexity, and eliminates the need for specialized handling while preserving efficient ODN delivery
4Productivity
If traditional cationic peptides or polysaccharides are used for ODN delivery, then cellular uptake is enhanced, but covalent binding requires elaborate chemistry tools
Solution Approach 1:
The cationic peptide serves as a non-covalent intermediary carrier that binds ODN through electrostatic interactions. This non-covalent binding mechanism eliminates the need for elaborate covalent conjugation chemistry while maintaining enhanced cellular uptake efficiency. The complex can be simply prepared by mixing the cationic peptide and anionic ODN in aqueous solution
Solution Approach 2:
The patent replaces the mechanical/chemical process of covalent bond formation with a simpler electrostatic attraction mechanism. Instead of requiring chemical reagents, catalysts, and elaborate conjugation protocols, the system uses natural electrostatic interactions between cationic peptides and anionic ODN to achieve stable complex formation and efficient cellular delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of protamine sulfate effectively increases the uptake and retention of antisense oligonucleotides in bladder cells, demonstrating potential therapeutic benefits by reducing nerve growth factor levels and alleviating bladder overactivity, while maintaining safety at lower concentrations.
Implementation Method 1
The binding between the negatively charged DNA phosphate groups and the cationic lipid or peptide carrier is achieved by ionic interaction
Data Source
AI summary
The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells.